JP2003520811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520811A5 JP2003520811A5 JP2001554399A JP2001554399A JP2003520811A5 JP 2003520811 A5 JP2003520811 A5 JP 2003520811A5 JP 2001554399 A JP2001554399 A JP 2001554399A JP 2001554399 A JP2001554399 A JP 2001554399A JP 2003520811 A5 JP2003520811 A5 JP 2003520811A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleoside
- cpg dinucleotide
- cpg
- internucleoside linkage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 47
- 239000002777 nucleoside Substances 0.000 claims 38
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 35
- 108091029430 CpG site Proteins 0.000 claims 29
- 238000000034 method Methods 0.000 claims 12
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 6
- 230000003308 immunostimulating effect Effects 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical group CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001965 increasing effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17856200P | 2000-01-26 | 2000-01-26 | |
| US60/178,562 | 2000-01-26 | ||
| PCT/US2001/002681 WO2001055370A2 (en) | 2000-01-26 | 2001-01-26 | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009180403A Division JP2009292829A (ja) | 2000-01-26 | 2009-08-03 | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520811A JP2003520811A (ja) | 2003-07-08 |
| JP2003520811A5 true JP2003520811A5 (enExample) | 2005-12-22 |
| JP4443810B2 JP4443810B2 (ja) | 2010-03-31 |
Family
ID=22653030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554399A Expired - Fee Related JP4443810B2 (ja) | 2000-01-26 | 2001-01-26 | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 |
| JP2009180403A Pending JP2009292829A (ja) | 2000-01-26 | 2009-08-03 | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009180403A Pending JP2009292829A (ja) | 2000-01-26 | 2009-08-03 | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6815429B2 (enExample) |
| EP (1) | EP1252307B1 (enExample) |
| JP (2) | JP4443810B2 (enExample) |
| AT (1) | ATE382690T1 (enExample) |
| AU (1) | AU783687B2 (enExample) |
| CA (1) | CA2398432C (enExample) |
| DE (1) | DE60132170T2 (enExample) |
| WO (1) | WO2001055370A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| EP2292632A3 (en) * | 2000-09-26 | 2012-07-25 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| KR100985457B1 (ko) | 2001-06-21 | 2010-10-06 | 다이나박스 테크놀로지 코퍼레이션 | 키메라 면역조절 화합물 및 그것들의 사용 방법 |
| US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| AU2002326561B2 (en) | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
| EA007232B1 (ru) * | 2001-08-17 | 2006-08-25 | Коли Фармасьютикал Гмбх | Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| DK1992635T3 (da) | 2002-12-23 | 2012-03-05 | Dynavax Tech Corp | Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse |
| JP4726630B2 (ja) | 2003-01-16 | 2011-07-20 | イデラ ファーマシューティカルズ インコーポレイテッド | 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節 |
| US7354907B2 (en) | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| WO2004074454A2 (en) | 2003-02-20 | 2004-09-02 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| KR20060012622A (ko) | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
| MXPA06000619A (es) | 2003-07-15 | 2006-04-11 | Hybridon Inc | Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion. |
| JP4989225B2 (ja) | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 核酸親油性接合体 |
| NZ546275A (en) | 2003-10-30 | 2009-05-31 | Coley Pharm Gmbh | C-class oligonucleotides analogs with enhanced immunostimulatory potency |
| KR101138131B1 (ko) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
| WO2006080946A2 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| WO2006063252A2 (en) * | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| ES2544877T3 (es) | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| EP1942945B1 (en) | 2005-11-07 | 2011-10-19 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| EP3087988A3 (en) * | 2008-10-06 | 2017-03-01 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| KR101856462B1 (ko) | 2009-03-25 | 2018-05-10 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물 |
| CN107012149A (zh) | 2010-11-19 | 2017-08-04 | 艾德拉药物股份有限公司 | 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物 |
| WO2012102793A2 (en) | 2010-12-10 | 2012-08-02 | Zirus, Inc. | Mammalian genes involved in toxicity and infection |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
| US5532130A (en) * | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
-
2001
- 2001-01-26 WO PCT/US2001/002681 patent/WO2001055370A2/en not_active Ceased
- 2001-01-26 AU AU31193/01A patent/AU783687B2/en not_active Ceased
- 2001-01-26 DE DE60132170T patent/DE60132170T2/de not_active Expired - Lifetime
- 2001-01-26 US US09/770,602 patent/US6815429B2/en not_active Expired - Fee Related
- 2001-01-26 EP EP01903365A patent/EP1252307B1/en not_active Expired - Lifetime
- 2001-01-26 JP JP2001554399A patent/JP4443810B2/ja not_active Expired - Fee Related
- 2001-01-26 CA CA2398432A patent/CA2398432C/en not_active Expired - Fee Related
- 2001-01-26 AT AT01903365T patent/ATE382690T1/de not_active IP Right Cessation
-
2002
- 2002-12-09 US US10/314,647 patent/US7329648B2/en not_active Expired - Fee Related
-
2009
- 2009-08-03 JP JP2009180403A patent/JP2009292829A/ja active Pending